|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3389699 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16876612.9 |
| Date of filing the European patent application | 2016-12-14 | |
| (97) | Date of publication of the European application | 2018-10-24 |
| (45) | Date of publication and mention of the grant of the patent | 2024-05-01 |
| (46) | Date of publication of the claims translation | 2024-06-10 |
| (86) | Number | PCT/US2016/066698 |
| Date | 2016-12-14 |
| (87) | Number | WO 2017/106372 |
| Date | 2017-06-22 |
| (30) | Number | Date | Country code |
| 201562267735 P | 2015-12-15 | US | |
| 201662309169 P | 2016-03-16 | US | |
| 201662359036 P | 2016-07-06 | US |
| (72) |
LIU, Yang , US
ZHENG, Pan , US
DEVENPORT, Martin , US
|
| (73) |
OncoC4, Inc. ,
9640 Medical Center Drive, Rockville, MD 20850,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Chimeriniai ir humanizuoti monokloniniai antikūnai prieš žmogaus CTLA4 ir jų panaudojimas |
| CHIMERIC AND HUMANIZED ANTI-HUMAN CTLA4 MONOCLONAL ANTIBODIES AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2024-11-04 | 9 | 208.00 EUR |
| 2025-12-14 |